Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up

Wojciech Jurczak, Alicja M. Gruszka, Anna Sowa Staszczak, Monika Dlugosz-Danecka, Marta Szostek, Dagmara Zimowska-Curylo, Agnieszka Giza, Katarzyna Krawczyk, Malgorzata Jakobczyk, Alicja Hubalewska-Dydejczyk, Michal Szymczyk, Tomasz Wróbel, Wanda Knopińska-Posłuszny, Elżbieta Kisiel, Aleksander Skotnicki, Pier Luigi Zinzani

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Consolidation with <sup>90</sup>Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up'. Together they form a unique fingerprint.

Medicine & Life Sciences